Compare Inovio Pharmaceuticals Inc (INO) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Upstart Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Upstart Holdings Inc trades at $29.66 (market cap $2.76B). The key difference: Upstart Holdings Inc is far larger — about 30.9× Inovio Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| INO | UPST | |
|---|---|---|
Market Cap | $89.27M | $2.76B |
Sector | Health | Financials |
52-Week High | $2.87 | $84.13 |
52-Week Low | $1.05 | $24.22 |
Enterprise Value | $60.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Upstart Holdings trades at $28.68, down 2.81% on the day, with a bearish technical signal but oversold RSI levels. The company reported a net income of $53.60M in 2025, a significant improvement from prior losses, though recent Q1 2026 earnings missed expectations. Revenue growth to $1.02B in 2025 and expanding AI lending platform into auto and home loans highlight operational progress.
The stock presents a recovery opportunity with analyst consensus target of $42.00, but faces risks from volatile earnings, high debt levels, and margin pressure. Investor sentiment is mixed amid ongoing execution challenges in a competitive fintech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
